Bristol pairs Yervoy safely with Opdivo vs lung cancer

(Reuters) - An early-stage study shows Bristol-Myers Squibb Co's Opdivo treatment can be safely and effectively paired with relatively low and infrequent dosages of the company's other immunotherapy, Yervoy, for patients with previously untreated lung cancer, researchers said on Monday.

Latest health news from http://reuters.us.feedsportal.com/c/35217/f/654207/s/49a4972e/sc/14/l/0L0Sreuters0N0Carticle0C20A150C0A90C0A70Cus0Ebristol0Emyers0Ecancer0Eopdivo0EidUSKCN0AR71W420A150A90A70DfeedType0FRSS0GfeedName0FhealthNews/story01.htm